Search

Your search keyword '"Inwards, David"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Inwards, David" Remove constraint Author: "Inwards, David" Publisher wiley Remove constraint Publisher: wiley
61 results on '"Inwards, David"'

Search Results

1. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

2. Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience

3. Long‐term outcome of immunologic autograft engineering

4. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

5. Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

6. Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma

8. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

9. Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia

10. Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation

11. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

12. Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

13. Impact of MYD88 L265P mutation status on histological transformation of Waldenström Macroglobulinemia

14. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes

15. Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

16. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018

17. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

19. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

20. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy

21. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma

22. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy

23. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

24. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

25. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

27. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma

28. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement

29. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

31. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma

32. Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

34. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

35. A Phase II study of153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

38. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

40. Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group

41. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome

42. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

44. Absolute lymphocyte count predicts overall survival in follicular lymphomas

46. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma

49. Author reply

Catalog

Books, media, physical & digital resources